ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / BMGL
ALPS (52) EUDA (39) NAKA (18) LFMD (32) ⌘ Pro Terminal →

Basel Medical Group Ltd (BMGL) — RQD Stock Rating Cockpit

$5.04 +6.11% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.09

Basel Medical Group Ltd (BMGL) carries a Roarable Rating of D+ (Sell) with 53/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $68.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BMGL Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BMGL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Basel Medical Group Ltd (NASDAQ: BMGL) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $5.04 (+6.11% 1D, market cap $68.5M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, BMGL ranks #237 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BMGL compare to ALPS and EUDA in the Health Care sector?
▼

Within the Health Care sector (Medical/Nursing Services), BMGL carries a Roarable D+ (53/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ALPS (ALPS Group Inc Ordinary Share) holds a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $54.1M) and EUDA (EUDA Health Holdings Limited) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $53.0M). Among the 5-stock peer group, BMGL leads on earnings multiple (N/A) while LFMD leads on capital efficiency (-26.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BMGL?
▼

For Basel Medical Group Ltd (BMGL), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #237 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $5.09 (+0.91%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 53/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.9% avg 90D alpha vs SPY • 50.6% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510053
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+
Cash (12)Whales (9)SEC (13)Macro (10)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-2.2% Base Target
$20 Bull$5 Base$4 Bear
📬 FREE BMGL RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BMGL)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (53/100 Composite)
🔍 WHY BMGL SCORES 53/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (23% of score)

SEC XBRL Trailing 12 Months: 0% FCF Margin ($1.9M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
45
Grade D$3.85+8.6% Next Q
Q2 (-2Q)
48
Grade D$4.18+10.8% Next Q
Q3 (-1Q)
50
Grade C-$4.63+8.9% Next Q
Current
53
Grade D+$5.04-0.9% Hist 90D α
Trajectory: D (45) → D+ (53)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BMGL Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BMGL currently carries a cautious 53/100 (D+) rating due to Insider Conviction & Share Dilution (9/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.37) and Max Pain ($5.29) forces dealer call-delta covering toward $19.66.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BMGL• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BMGL Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 53%NO 47%Trade / Inspect Odds →
RSI-14 MOMENTUMBULLISH MOMENTUM
64.130 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
7 / 99-Pt Accounting
52-WEEK LASER RANGE15% OF RANGE
L: $3$5.04H: $19
1. Money & Cash Health● MIXED
Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 18 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 23 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on BMGL

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
NEUTRAL (60)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (47)

18/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like BMGL
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BMGL)

  • ✓Walkthrough of BMGL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
BMGL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -27.38%▼ DESCENDING CHANNEL
2026-11-03O $4.75H $5.04L $4.75C $5.04VOL 1.78M
RES: $8.23SUP: $1.87SMA50: $4.37SMA200: $6.43
$15.08$11.69$8.29$4.90$1.51RES $8.23SUP $1.87$5.042026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BMGL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BMGL Butterfly Map → + Track BMGL →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BMGL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BMGL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BMGL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BMGL)

Health Care Rank #237 of 1015 ⚔️ ALPS vs BMGL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BMGL vs. ALPS, EUDA, NAKA, LFMD)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Basel Medical Group Ltd (BMGL) ranks #237 by composite RQD confidence (53/100, grade D+) and #701 by equity capitalization ($68.5M). Within this direct 5-issuer industry benchmark cohort, BMGL leads on earnings valuation at N/A trailing P/E, while LFMD leads on capital efficiency and profitability with -26.2% ROIC and 85.7% gross margin. BMGL currently leads its immediate peer cohort in composite quantitative strength at 53/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BMGL ACTIVE
Basel Medical Group Ltd
D+ 53/100 — — — +6.11% $68.5M Benchmark Subject
ALPS
ALPS Group Inc Ordinary Share
D+ 52/100 — — — +0.03% $54.1M /alps-vs-bmgl →
EUDA
EUDA Health Holdings Limited
D- 39/100 — 43.9% -35.0% +14.19% $53.0M /euda-vs-bmgl →
NAKA
Nakamoto Inc.
E 18/100 — — -31.6% -14.83% $107.5M /naka-vs-bmgl →
LFMD
LifeMD Inc.
E 32/100 — 85.7% -26.2% -1.29% $110.4M /lfmd-vs-bmgl →

2. BMGL Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Basel Medical Group Ltd (BMGL) operates in Medical/Nursing Services (Health Care) with an equity capitalization of $68.5M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. BMGL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BMGL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Basel Medical Group Ltd (NASDAQ: BMGL) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $5.04 (+6.11% 1D, market cap $68.5M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, BMGL ranks #237 in composite RQD confidence.

How does BMGL compare to ALPS and EUDA in the Health Care sector?

Within the Health Care sector (Medical/Nursing Services), BMGL carries a Roarable D+ (53/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ALPS (ALPS Group Inc Ordinary Share) holds a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $54.1M) and EUDA (EUDA Health Holdings Limited) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $53.0M). Among the 5-stock peer group, BMGL leads on earnings multiple (N/A) while LFMD leads on capital efficiency (-26.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BMGL?

For Basel Medical Group Ltd (BMGL), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #237 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BMGL trading relative to its 50-day, 200-day, and 52-week technical levels?

BMGL last traded at $5.04 (+6.11% on volume of 1,782,262 shares), positioning the stock +15.33% above its 50-day simple moving average ($4.37) and -21.62% below its 200-day simple moving average ($6.43). Across its 52-week range of $2.56 to $18.72, BMGL sits at the 15.3% percentile with a 14-day RSI of 64.1 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($4.41 to $5.67).

Direct Sub-Reports: BMGL RQD Cockpit BMGL 12M Forecast BMGL Earnings & Move BMGL Dividends & DRIP BMGL Insiders & 13F BMGL Whale Options BMGL Profit Sankey BMGL News & Why
ROARABLE RATING BRIEF • RQD 53/100 (D+) ✓ SEC XBRL & RQD VERIFIED

BMGL — Basel Medical Group Ltd: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

Basel Medical Group Ltd (BMGL) earns a live Roarable RQD composite score of 53/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $5.04 (+6.11% 1D, market capitalization $68.5M).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (9/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Basel Medical Group Ltd (BMGL) is a NASDAQ-listed operating company in the Medical/Nursing Services industry (Health Care sector) with an equity market capitalization of $68.5M. The business operates with a gross margin of 0%, an operating margin of 0%, and a return on invested capital (ROIC) of 0% (free cash flow yield of 0%). Within the Medical/Nursing Services peer group, investor evaluation centers on operating leverage, unit margin durability, and capital allocation efficiency across market cycles.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D+ • RQD 53/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 9/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $2.56 – $18.72 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Second-order bottlenecks cannot be identified from the sources.

  • Key Question #1: Can BMGL sustain or expand its — operating margin and — ROIC against Medical/Nursing Services peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $18.72 52-week high?
  • Key Question #3: How sensitive is BMGL's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

BMGL Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Basel Medical Group Ltd (BMGL) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BMGL Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BMGL Bull vs. Bear Conversation Board — What's Your Call at $5.04?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BMGL 🐻 33% BEARISH CONVICTION
1. Pick Your Side on BMGL:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $6.20 (+23.0%)
📌 Pinned Debate

Forensic balance sheet metrics (Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) are the strongest pillar at 13 of 20.

The street is overcomplicating Basel Medical Group Ltd (BMGL). Forensic balance sheet metrics (Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) are the strongest pillar at 13 of 20.. With an RQD score of 53/100 (D+) and Forensic Balance Sheet at 13/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $5.44.

ArenaChamp_24 🐂 BULL

@SkepticalCFA Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Medical/Nursing Services. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $4.33 (-14.1%)
Spot @ $5.04

Zero reported ROIC and zero FCF yield leave the Fundamental Cash Engine pillar at 12 of 20 with no measured cash return.

Zero reported ROIC and zero FCF yield leave the Fundamental Cash Engine pillar at 12 of 20 with no measured cash return.. Look at the math on BMGL: paying current EV/EBITDA multiples for 0.0% ROIC and 0.0% operating margins leaves zero margin of safety if Medical/Nursing Services demand softens. I'd wait for a retest of $4.44 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%